Literature DB >> 34472840

Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2.

Xuan Qin1, Hailing Chen1, Licheng Tu1, Yue Ma1, Na Liu2, Haowei Zhang3, Di Li1, Bernd Riedl4, Donald Bierer4, Feng Yin2, Zigang Li1,2.   

Abstract

Disrupting the interaction between HIF1α and p300 is a promising strategy to modulate the hypoxia response of tumor cells. Herein, we designed a constrained peptide inhibitor derived from the CITED2/p300 complex to disturb the HIF1α/p300 interaction. Through truncation/mutation screening and a terminal aspartic acid-stabilized strategy, a constrained peptide was constructed with outstanding biochemical/biophysical properties, especially in binding affinity, cell penetration, and serum stability. To date, our study was the first one to showcase that stabilized peptides derived from CITED2 using helix-stabilizing methods acted as a promising candidate for modulating hypoxia-inducible signaling.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34472840     DOI: 10.1021/acs.jmedchem.1c01043

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Understanding p300-transcription factor interactions using sequence variation and hybridization.

Authors:  Fruzsina Hóbor; Zsófia Hegedüs; Amaurys Avila Ibarra; Vencel L Petrovicz; Gail J Bartlett; Richard B Sessions; Andrew J Wilson; Thomas A Edwards
Journal:  RSC Chem Biol       Date:  2022-04-11

2.  The combined use of acetazolamide and Rhodiola in the prevention and treatment of altitude sickness.

Authors:  Chengzhu Cao; Huan Zhang; Yongchun Huang; Yameng Mao; Lan Ma; Shoude Zhang; Wei Zhang
Journal:  Ann Transl Med       Date:  2022-05

3.  The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication.

Authors:  Christian Albert Devaux; Didier Raoult
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.